Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

195.26USD
15 Aug 2018
Change (% chg)

$-0.50 (-0.26%)
Prev Close
$195.76
Open
$194.83
Day's High
$195.48
Day's Low
$192.89
Volume
832,685
Avg. Vol
1,297,123
52-wk High
$201.23
52-wk Low
$163.31

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $126,612.90
Shares Outstanding(Mil.): 647.27
Dividend: 1.32
Yield (%): 2.70

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 16.29 28.54 30.58
EPS (TTM): 12.02 -- --
ROI: 13.20 13.15 12.84
ROE: 36.30 15.15 15.02

UPDATE 3-Teva Pharm shares sink as sales forecast disappoints market

* Company still sees FDA approval of migraine drug mid-September

02 Aug 2018

Amgen profit beats Street view, will not raise prices again in 2018

Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

26 Jul 2018

UPDATE 2-Amgen profit beats Street view, will not raise prices again in 2018

July 26 Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

26 Jul 2018

Amgen CEO says will not raise drug prices again this year

Amgen Inc Chief Executive Robert Bradway said on Thursday that the biotechnology company will not raise drug prices for the remainder of the year.

26 Jul 2018

Amgen CEO says will not raise drug prices again this year

July 26 Amgen Inc Chief Executive Robert Bradway said on Thursday that the biotechnology company will not raise drug prices for the remainder of the year.

26 Jul 2018

Amgen quarterly profit beats Wall Street view on new product sales

July 26 Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year forecast, as growth of newer drugs like cholesterol fighter Repatha and osteoporosis drug Prolia offset weakness in older products.

26 Jul 2018

RPT-FOCUS-Amgen's new migraine drug hits insurance hurdles

July 26 Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

26 Jul 2018

Amgen's new migraine drug hits insurance hurdles

Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

26 Jul 2018

FOCUS-Amgen's new migraine drug hits insurance hurdles

July 26 Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

26 Jul 2018

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases.

15 Jun 2018

Earnings vs. Estimates